These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 10410857)
21. [The most common cutaneous vasculitides. Often life-threatening]. Schulz H MMW Fortschr Med; 2010 Nov; 152(46):43-5. PubMed ID: 21229725 [No Abstract] [Full Text] [Related]
22. Cutaneous drug reactions in the pediatric population. Noguera-Morel L; Hernández-Martín Á; Torrelo A Pediatr Clin North Am; 2014 Apr; 61(2):403-26. PubMed ID: 24636653 [TBL] [Abstract][Full Text] [Related]
23. Recognition and management of severe cutaneous drug reactions. Knowles SR; Shear NH Dermatol Clin; 2007 Apr; 25(2):245-53, viii. PubMed ID: 17430761 [TBL] [Abstract][Full Text] [Related]
24. [Adverse cutaneous reactions to drugs]. Suástegui-Rodríguez I; Campos-Jiménez KI; Domínguez-Cherit J; Méndez-Flores S Rev Med Inst Mex Seguro Soc; 2018; 56(1):64-70. PubMed ID: 29368897 [TBL] [Abstract][Full Text] [Related]
25. An update on pediatric cutaneous drug eruptions. Song JE; Sidbury R Clin Dermatol; 2014; 32(4):516-23. PubMed ID: 25017462 [TBL] [Abstract][Full Text] [Related]
26. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. Nigen S; Knowles SR; Shear NH J Drugs Dermatol; 2003 Jun; 2(3):278-99. PubMed ID: 12848112 [TBL] [Abstract][Full Text] [Related]
27. The role of histological presentation in erythroderma. Megna M; Sidikov AA; Zaslavsky DV; Chuprov IN; Timoshchuk EA; Egorova U; Wenzel J; Nasyrov RA Int J Dermatol; 2017 Apr; 56(4):400-404. PubMed ID: 28191631 [TBL] [Abstract][Full Text] [Related]
28. [Current problems in the treatment and prevention of drug-induced toxicodermas]. Tarasenko GN; Basalkevich GP; Patronov IV; Peredernin SF; Tarasenko IuG; Sebekina OV Voen Med Zh; 2000 Mar; 321(3):33-6. PubMed ID: 10815537 [No Abstract] [Full Text] [Related]
32. Drug eruptions in children: a review of 111 cases seen in a tertiary skin referral centre. Khoo BP; Giam YC Singapore Med J; 2000 Nov; 41(11):525-9. PubMed ID: 11284609 [No Abstract] [Full Text] [Related]
33. Chronic eczematous eruptions in the aging: further support for an association with exposure to calcium channel blockers. Summers EM; Bingham CS; Dahle KW; Sweeney C; Ying J; Sontheimer RD JAMA Dermatol; 2013 Jul; 149(7):814-8. PubMed ID: 23636109 [TBL] [Abstract][Full Text] [Related]
34. Cutaneous Manifestation of Drug Allergy and Hypersensitivity. Zalewska-Janowska A; Spiewak R; Kowalski ML Immunol Allergy Clin North Am; 2017 Feb; 37(1):165-181. PubMed ID: 27886905 [TBL] [Abstract][Full Text] [Related]
35. [Cutaneous drug reactions: diagnosis and etiology]. Bonnetblanc JM; Nouaille Y Rev Prat; 2000 Jun; 50(12):1300-4. PubMed ID: 10972069 [TBL] [Abstract][Full Text] [Related]
38. [Cutaneous side effects of targeted cancer drugs]. Below J; Homey B; Gerber PA Hautarzt; 2017 Jan; 68(1):12-18. PubMed ID: 27885401 [TBL] [Abstract][Full Text] [Related]
39. Eczematous infiltrated plaques to subcutaneous heparin: a type IV allergic reaction. Bircher AJ; Flückiger R; Buchner SA Br J Dermatol; 1990 Oct; 123(4):507-14. PubMed ID: 2151304 [TBL] [Abstract][Full Text] [Related]
40. [Bullous dermatosis at distant sites in patients treated with heparin]. Castellanos-González M; Velasco-Rodríguez D; Mancebo Plaza AB Med Clin (Barc); 2016 May; 146(9):402-7. PubMed ID: 26701130 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]